This research is necessary because pancreatic cancer surgery is only useful if metastases are absent. But metastases are often difficult to detect. As a result, patients sometimes undergo a major operation that turned out to be unnecessary afterwards. In addition, half of the patients after this major operation are not fit enough to undergo chemotherapy after all.
It is known that patients with an inoperable pancreatic tumor often live longer and more pleasantly because of the chemotherapy FOLFIRINOX. Do patients whose pancreatic tumor can be removed via surgery also benefit from this chemotherapy?
With this research, the researchers want to study whether a certain chemotherapy prior to pancreatic cancer surgery is more effective than an operation followed by chemotherapy (the current standard).